Eris Lifesciences Limited (BOM:540596)
1,319.50
-8.40 (-0.63%)
At close: Nov 20, 2026
Eris Lifesciences Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Eris Lifesciences stock has a consensus rating of "Strong Buy" and an average price target of ₹1,511. The average 1-year stock price forecast is 14.51% higher than the current stock price, while the lowest is ₹1,140 (-13.60%) and the highest is ₹1,780 (+34.90%).
Price Target: ₹1,511 (+14.51%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Eris Lifesciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 8 | 9 | 9 |
| Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 10 | 10 |
Financial Forecast
Revenue This Year
33.78B
from 31.15B
Increased by 8.45%
Revenue Next Year
39.79B
from 33.78B
Increased by 17.79%
EPS This Year
43.71
from 46.52
Decreased by -6.03%
EPS Next Year
55.81
from 43.71
Increased by 27.68%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.